IN THE CLAIMS:

Please cancel claims 36, 37, 41, 42, 44, 45 and 49-66. Please amend claims 35, 40, 43, and 48. This listing of claims will replace all prior versions, and listings, of claims in the application:

In the claims:

- 1-34. (Canceled)
- 35. (Currently Amended): A method for identifying a candidate compound <u>capable of binding to a polypeptide selected from the group consisting of:</u>

for modulating a pain disorder, the method comprising:

- i) combining a compound to be tested with a sample comprising a polypeptide selected from the group consisting of:
 - a) a polypeptide which is at least 95% identical to the amino acid sequence of SEQ ID
 NO:2, wherein the polypeptide exhibits carboxylesterase activity; and
 - a polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:1 or SEQ
 ID NO:3, wherein the polypeptide exhibits carboxylesterase activity;

the method comprising:

- i) combining a compound to be tested with a sample comprising a cell expressing the polypeptide under conditions suitable for binding;
 - ii) assessing the ability of the compound to bind to the polypeptide; and
 - iii) selecting a compound capable of binding to the polypeptide;

wherein the cell is selected from the group consisting of a brain cell, a cell derived from spinal cord, and a cell derived from dorsal root ganglion;

thereby identifying a candidate compound <u>capable of binding to the polypeptide</u> for modulating a pain disorder.

- 36. (Canceled).
- 37. (Canceled).
- 38. (Previously Presented): The method of claim 35, wherein the compound is selected from the group consisting of a small molecule, a peptide or an antibody.

39. (Previously Presented):	The method of claim 35, wherein the polypeptide further comprises
heterologous sequences.	
•	

- 40. (Currently Amended): The method of claim 35, wherein the binding of the test compound to the polypeptide is determined by a method selected from the group consisting of:
 - a) direct detecting of test compound/polypeptide binding;
 - b) a competition binding assay; and
 - c) an immunoassay;
- e) an assay for lipid metabolism.
- 41. (Canceled).
- 42. (Canceled).
- 43. (Currently Amended): A method for identifying a candidate compound <u>capable of binding to a polypeptide selected from the group consisting of:</u> for modulating a pain disorder, the method comprising:
 - i) combining a compound to be tested with a sample comprising a polypeptide selected from the group consisting of:
 - a) a polypeptide comprising the amino acid sequence of SEQ ID NO:2; and
 - b) a polypeptide encoded by the nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:3;

the method comprising:

- i) combining a compound to be tested with a sample comprising a cell expressing the polypeptide under conditions suitable for binding;
- ii) assessing the ability of the compound to bind to the polypeptide; and
- iii) selecting a compound capable of binding to the polypeptide;

wherein the cell is selected from the group consisting of a brain cell, a cell derived from spinal cord, and a cell derived from dorsal root ganglion;

thereby identifying a candidate compound <u>capable of binding to the polypeptide</u> for modulating a pain disorder.

44. (Canceled).

45.	(Cancel	led)	١.
	(,	•

- 46. (Previously Presented): The method of claim 43, wherein the compound is selected from the group consisting of a small molecule, a peptide or an antibody.
- 47. (Previously Presented): The method of claim 43, wherein the polypeptide further comprises heterologous sequences.
- 48. (Currently Amended): The method of claim 43, wherein the binding of the test compound to the polypeptide is determined by a method selected from the group consisting of:
 - a) direct detecting of test compound/polypeptide binding;
 - b) a competition binding assay; and
 - c) an immunoassay;
- ----d) a yeast two-hybrid assay; and
- e) an assay for an assay for lipid metabolism.

49-66. (Canceled).